TrialDiabetes, obesity & metabolism2026

Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.

Shraddha Shinde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.